Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Asset Writedowns and Impairment (2016 - 2019)

International Stem Cell (ISCO) has disclosed Asset Writedowns and Impairment for 9 consecutive years, with $1.4 million as the latest value for Q4 2019.

  • On a quarterly basis, Asset Writedowns and Impairment rose 467.07% to $1.4 million in Q4 2019 year-over-year; TTM through Sep 2024 was $1.4 million, a N/A change, with the full-year FY2024 number at $2000.0, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $1.4 million for Q4 2019 at International Stem Cell, up from $246000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 million in Q4 2019 to a low of $2000.0 in Q2 2016.
  • A 5-year average of $245533.3 and a median of $93000.0 in 2018 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: plummeted 96.15% in 2016, then soared 3804.17% in 2017.
  • International Stem Cell's Asset Writedowns and Impairment stood at $77000.0 in 2015, then plummeted by 68.83% to $24000.0 in 2016, then skyrocketed by 3804.17% to $937000.0 in 2017, then plummeted by 73.75% to $246000.0 in 2018, then soared by 467.07% to $1.4 million in 2019.
  • Per Business Quant, the three most recent readings for ISCO's Asset Writedowns and Impairment are $1.4 million (Q4 2019), $246000.0 (Q4 2018), and $157000.0 (Q3 2018).